Digestive System Disease Clinical Trial
— ECAPOfficial title:
Creation and Validation of a Clinical Evaluation Scale for Abdominal Condition of the Premature
Verified date | April 2023 |
Source | University Hospital, Clermont-Ferrand |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Observational |
Every year in France, 60,000 children are born prematurely (before 37 weeks of amenorrhea), and present an immaturity of their various systems, in particular the digestive system. This can result in feeding intolerance, which is expressed by abdominal distension, regurgitation or vomiting, irregular transit and abdominal discomfort. This feeding intolerance influences the length of hospitalization and can lead to necrotising enterocolitis, a major complication. In the Neonatal Intensive Care Units of Clermont-Ferrand hospital center, abdominal massages have been performed by physiotherapists for several years in order to improve the condition of the digestive system. However, the indication for abdominal massage is very dependent on the caregivers in charge of the newborn and the evaluation of the abdominal condition remains subjective with a great variability between examiners. Thus, some newborns will receive massage multiple times a day while others will not. Developmental care is essential for these premature infants, especially to avoid over-stimulation. It is important not to add care, such as massage, if it is not needed. It is therefore essential to properly assess the digestive status of premature babies in order to determine whether they have feeding intolerance and whether they require treatment with abdominal massage. To date, the investigators have not found measurable criteria or existing scales that can describe the digestive status of newborns. The main objective of the study is therefore to create and validate a clinical assessment scale for the abdominal status of preterm infants.
Status | Completed |
Enrollment | 120 |
Est. completion date | September 1, 2023 |
Est. primary completion date | September 1, 2023 |
Accepts healthy volunteers | |
Gender | All |
Age group | 3 Days to 60 Days |
Eligibility | Inclusion Criteria: - newborns, born prematurely (before 37 weeks of amenorrhea) - at least 3 days of life - hospitalized in the neonatal intensive care units - whose holders of parental authority are able to give free and informed consent to participate in this study Exclusion Criteria: - Newborns with congenital pathology such as malformation, genetic or chromosomal abnormality. - Newborns whose holders of parental authority are protected by law (under guardianship) or under the age of 18. - Rejection of participation by parents |
Country | Name | City | State |
---|---|---|---|
France | CHU clermont-ferrand | Clermont-ferrand |
Lead Sponsor | Collaborator |
---|---|
University Hospital, Clermont-Ferrand |
France,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Clinical Abdominal assessment scale for Preterm infant (ECAP scale) | score between 0 and 20 | up to 18 months | |
Secondary | Indication for abdominal massage on ECAP scale | score on the Clinical Abdominal assessment scale for Preterm infants, between 0 and 20 (higher scores meaning worse outcome) | up to 18 months | |
Secondary | ECAP scale validity | term of birth population | up to 18 months | |
Secondary | impact of massage on ECAP scale | variation of the score of Clinical Abdominal assessment scale for Preterm infants, between 0 and 20 (higher scores meaning worse outcome) | up to 18 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05066139 -
Multidisciplinary Evaluation of Elderly Patients With Digestive Cancer (EPODIG-G)
|
N/A | |
Recruiting |
NCT04475952 -
Early Diagnosis of Upper Digestive Tract Disease
|
||
Completed |
NCT05064163 -
SROI Project on the Surgical Waiting List Management System
|
||
Completed |
NCT03559543 -
Evaluation of Ocoxin®-Viusid® in Metastatic Colorectal Adenocarcinoma
|
Phase 2 | |
Completed |
NCT03549494 -
Evaluation of Ocoxin®-Viusid® in Advanced Stomach Cancer and Gastric Esophagogastric Junction
|
Phase 2 | |
Completed |
NCT03723447 -
Intraoperative TAP Block With Bupivacaine/Dexamethasone Against Liposomal Bupivacaine (Exparel®)
|
Phase 4 | |
Enrolling by invitation |
NCT01483248 -
Human Menstrual Blood-derived Mesenchymal Stem Cells for Patients With Liver Cirrhosis
|
Phase 1/Phase 2 | |
Completed |
NCT03008460 -
Efficacy, Safety and Tolerability of Eziclen®/Izinova® Versus Klean-prep® on Bowel Cleansing in Adolescents Undergoing Colonoscopy
|
Phase 3 | |
Active, not recruiting |
NCT05253859 -
CFTR Modulators and Gastrointestinal Complications
|
||
Not yet recruiting |
NCT05636657 -
Comparative Study of Intestinal Color Ultrasound and Capsule Endoscopy in Monitoring Crohn's Disease
|
||
Completed |
NCT05160077 -
Optoacoustic Characterization of Postprandial Intestinal Blood Flow
|
N/A | |
Recruiting |
NCT05401058 -
Low-dose Droperidol for Prevention of Postoperative Delirium in Elderly Patients After Non-cardiac Surgery
|
N/A | |
Completed |
NCT06283732 -
A Clinical Study to Assess the Effect of a Supplement on Digestive Health, Overall Well-being, and Participant Experience.
|
N/A | |
Not yet recruiting |
NCT06271538 -
Evaluation of Efficacy of Skål Pro Powder on Symptoms of Irritable Bowel Syndrome
|
Phase 4 | |
Terminated |
NCT03594331 -
Gastric Gluten-Degradation Activity of PvP001
|
Phase 1 | |
Not yet recruiting |
NCT05405842 -
Transauricular Vagal Nerve Stimulation; Functional Dyspepsia and Gastroparesis
|
N/A | |
Recruiting |
NCT06351202 -
Impact Assessment of Abdominal Massage on Feeding Tolerance of Preterms
|
N/A | |
Completed |
NCT02785783 -
Endorings™ Assisted Colonoscopy Versus Standard Colonoscopy for Polyp Detection
|
N/A | |
Completed |
NCT00072943 -
A Humanized Anti-Interferon-γ Monoclonal Antibody (HuZAF) for Moderate to Severe Crohn's Disease
|
Phase 2 | |
Completed |
NCT03037385 -
Phase 1/2 Study of the Highly-selective RET Inhibitor, Pralsetinib (BLU-667), in Participants With Thyroid Cancer, Non-Small Cell Lung Cancer, and Other Advanced Solid Tumors
|
Phase 1/Phase 2 |